Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 2/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678250 | 0.86 | SMN1; SMN2 (0.52) | LMNASMN1; SMN2ALDH1A1HPGDALPL | |
| SCHEMBL6676852 | 0.86 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2ALDH1A1HPGDALPL | |
| SCHEMBL6678265 | 0.84 | MAPT (0.46) | LMNASMN1; SMN2ALDH1A1ATMALPL | |
| SCHEMBL6675225 | 0.83 | LMNA (0.56) | LMNASMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL6676916 | 0.83 | ALPL (0.45) | LMNASMN1; SMN2ALDH1A1HPGDALPL | |
| SCHEMBL6673886 | 0.82 | ALDH1A1 (0.51) | LMNASMN1; SMN2ALDH1A1HPGDATM | |
| SCHEMBL6675270 | 0.80 | LMNA (0.52) | LMNASMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL6676773 | 0.80 | LMNA (0.52) | LMNASMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL6680003 | 0.77 | LMNA (0.58) | LMNASMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL6679367 | 0.76 | ALDH1A1 (0.57) | LMNASMN1; SMN2ALDH1A1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | claimed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | claimed |
| EP-1005453-B1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE LOWERING AGENTS | TULARIK INC (US) | 2004-10-27 | — | — | EP | disclosed |
| US-6388131-B2 | Benzenesulfonamide compounds, which encompasses the compound batabulin (2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene) | TULARIK, INC. | 2002-05-14 | — | — | US | disclosed |
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | disclosed |
| US-6284923-B1 | BENZENESULFONIMIDES FOR TREATMENT OF CANCER AND ANTICHOLESTEROL AGENTS | TULARIK INC | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | CYP46A1, TGFB1, NR1H2 | LMNA 2006/4885SMN1; SMN2 4446/4885ALDH1A1 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.